<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36457320</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>A 12-month projection to September 2022 of the COVID-19 epidemic in the UK using a dynamic causal model.</ArticleTitle><Pagination><StartPage>999210</StartPage><MedlinePgn>999210</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">999210</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2022.999210</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Predicting the future UK COVID-19 epidemic allows other countries to compare their epidemic with one unfolding without public health measures except a vaccine program.</AbstractText><AbstractText Label="METHODS">A Dynamic Causal Model was used to estimate key model parameters of the UK epidemic, such as vaccine effectiveness and increased transmissibility of Alpha and Delta variants, the effectiveness of the vaccine program roll-out and changes in contact rates. The model predicts the future trends in infections, long-COVID, hospital admissions and deaths.</AbstractText><AbstractText Label="RESULTS">Two-dose vaccination given to 66% of the UK population prevents transmission following infection by 44%, serious illness by 86% and death by 93%. Despite this, with no other public health measures used, cases will increase from 37 million to 61 million, hospital admissions from 536,000 to 684,000 and deaths from 136,000 to 142,000 over 12 months. A retrospective analysis (conducted after the original submission of this report) allowed a comparison of these predictions of morbidity and mortality with actual outcomes.</AbstractText><AbstractText Label="CONCLUSION">Vaccination alone will not control the epidemic. Relaxation of mitigating public health measures carries several risks, which include overwhelming the health services, the creation of vaccine resistant variants and the economic cost of huge numbers of acute and chronic cases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Bowie and Friston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowie</LastName><ForeName>Cam</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Retired, Axminster, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friston</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Neuroimaging, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">compartmental models</Keyword><Keyword MajorTopicYN="N">epidemiology&#x2014;descriptive</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">public health methodology</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36457320</ArticleId><ArticleId IdType="pmc">PMC9705757</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2022.999210</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Friston KJ, Parr T, Zeidman P, Razi A, Flandin G, Daunizeau J, et al. . Dynamic causal modelling of COVID-19. Wellcome Open Res. (2020) 5:89. 10.12688/wellcomeopenres.15881.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15881.1</ArticleId><ArticleId IdType="pmc">PMC7431977</ArticleId><ArticleId IdType="pubmed">32832701</ArticleId></ArticleIdList></Reference><Reference><Citation>Karl, Friston,. Dynamic Causal Modelling of COVID-19; Dashboard . Available online at: https://www.fil.ion.ucl.ac.uk/spm/covid-19/ (accessed May 24, 2021).</Citation></Reference><Reference><Citation>Gandolfi D, Pagnoni G, Filippini T, Goffi A, Vinceti M, D'Angelo E, et al. . Modeling early phases of COVID-19 pandemic in Northern Italy and its implication for outbreak diffusion. Front Public Health. (2021) 9:e724362. 10.3389/fpubh.2021.724362</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.724362</ArticleId><ArticleId IdType="pmc">PMC8716563</ArticleId><ArticleId IdType="pubmed">34976909</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran RJ, Fagerholm ED, Cullen M, Daunizeau J, Richardson MP, Williams S, et al. . Estimating required &#x201c;lockdown&#x201d; cycles before immunity to SARS-CoV-2: Model-based analyses of susceptible population sizes, &#x201c;S0&#x201d;, in seven European countries including the UK and Ireland. arXiv:200405060 [q-bio]. (2020). 10.1101/2020.04.10.20060426</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.10.20060426</ArticleId></ArticleIdList></Reference><Reference><Citation>Daunizeau J, Moran R, Brochard J, Mattout J, Frackowiak R, Friston K. Modelling Lockdown-Induced 2nd COVID Waves in France. New York, NY: Cold Spring Harbor Laboratory Press; (2020).</Citation></Reference><Reference><Citation>Dynamic Causal Modelling of COVID-19 and Australian Projections . Available online at: http://www.adeelrazi.org/predictions.html (accessed September 27, 2021).</Citation></Reference><Reference><Citation>Friston KJ, Parr T, Zeidman P, Razi A, Flandin G, Daunizeau J, et al. . Second waves, social distancing, and the spread of COVID-19 across the USA. Wellcome Open Res. (2021) 5:103. 10.12688/wellcomeopenres.15986.3</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15986.3</ArticleId><ArticleId IdType="pmc">PMC8063524</ArticleId><ArticleId IdType="pubmed">33954262</ArticleId></ArticleIdList></Reference><Reference><Citation>Osthus D, Hickmann KS, Caragea PC, Higdon D, Valle SYD. Forecasting seasonal influenza with a state-space SIR model. Ann Appl Stat. (2017) 11:202&#x2013;24. 10.1214/16-AOAS1000</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/16-AOAS1000</ArticleId><ArticleId IdType="pmc">PMC5623938</ArticleId><ArticleId IdType="pubmed">28979611</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher J. Forecasting Ebola with a regression transmission model. Epidemics. (2018) 22:50&#x2013;5. 10.1016/j.epidem.2017.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2017.02.009</ArticleId><ArticleId IdType="pubmed">28342787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi G, Sugasawa S, Tamae H, Ozu T. Predicting intervention effect for COVID-19 in Japan: state space modeling approach. Biosci Trends. (2020) 14:174&#x2013;81. 10.5582/bst.2020.03133</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2020.03133</ArticleId><ArticleId IdType="pubmed">32461511</ArticleId></ArticleIdList></Reference><Reference><Citation>MRC, Biostatistics Unit . Nowcasting and Forecasting of the COVID-19 Pandemic. In: MRC Biostatistics Unit. Available online at: https://www.mrc-bsu.cam.ac.uk/tackling-covid-19/nowcasting-and-forecasting-of-covid-19/ (accessed July 20, 2022).</Citation></Reference><Reference><Citation>Birrell P, Blake J, van Leeuwen E, Gent N, De Angelis D. Real-time nowcasting and forecasting of COVID-19 dynamics in England: the first wave. Philosop Trans R Soc B Biol Sci. (2021) 376:20200279. 10.1098/rstb.2020.0279</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2020.0279</ArticleId><ArticleId IdType="pmc">PMC8165585</ArticleId><ArticleId IdType="pubmed">34053254</ArticleId></ArticleIdList></Reference><Reference><Citation>Penny WD. Comparing dynamic causal models using AIC, BIC and free energy. Neuroimage. (2012) 59:319&#x2013;30. 10.1016/j.neuroimage.2011.07.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.07.039</ArticleId><ArticleId IdType="pmc">PMC3200437</ArticleId><ArticleId IdType="pubmed">21864690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: a tutorial. Statist Sci. (1999) 14:382&#x2013;401. 10.1214/ss/1009212519</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/ss/1009212519</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K, Parr T, Zeidman P. Bayesian model reduction. arXiv. New York, NY: Cornell University (2019) Preprint. 10.48550/arXiv.1805.07092</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.1805.07092</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K, Penny W. Post hoc Bayesian model selection. Neuroimage. (2011) 56:2089&#x2013;99. 10.1016/j.neuroimage.2011.03.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.03.062</ArticleId><ArticleId IdType="pmc">PMC3112494</ArticleId><ArticleId IdType="pubmed">21459150</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K, Mattout J, Trujillo-Barreto N, Ashburner J, Penny W. Variational free energy and the Laplace approximation. Neuroimage. (2007) 34:220&#x2013;34. 10.1016/j.neuroimage.2006.08.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.08.035</ArticleId><ArticleId IdType="pubmed">17055746</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MJ,. Variational algorithms for approximate Bayesian inference. (Doctoral thesis). University College London  (2003). Available online at: https://discovery.ucl.ac.uk/id/eprint/10101435/ (accessed October 31, 2022).</Citation></Reference><Reference><Citation>Winn J, Bishop CM. Variational message passing. J Mach Learn Res. (2005) 6:661&#x2013;94. Available online at: http://jmlr.org/papers/v6/winn05a.html</Citation></Reference><Reference><Citation>England Summary | Coronavirus (COVID-19) in the UK . Available online at: https://coronavirus.data.gov.uk (accessed October 14, 2022).</Citation></Reference><Reference><Citation>ONS . Coronavirus (COVID-19) Latest Insights - Office for National Statistics. Available online at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections (accessed September 27, 2022).</Citation></Reference><Reference><Citation>IHME. COVID-19 Estimation Updates. Institute for Health Metrics and Evaluation  (2020). Available online at: http://www.healthdata.org/covid/updates (accessed May 18, 2020).</Citation></Reference><Reference><Citation>Oxford, Tracker, . COVID-19 Government Response Tracker. Available online at: https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker (accessed September 27, 2022).</Citation></Reference><Reference><Citation>Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. . Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. (2021) 372:abg3055. 10.1126/science.abg3055</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. . Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. (2021) 26:2100509. 10.2807/1560-7917.ES.2021.26.24.2100509</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.24.2100509</ArticleId><ArticleId IdType="pmc">PMC8212592</ArticleId><ArticleId IdType="pubmed">34142653</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagpunar J. Interim Estimates of Increased Transmissibility, Growth Rate, and Reproduction Number of the Covid-19 B.1.617.2 Variant of Concern in the United Kingdom. New York, NY: Cold Spring Harbor Laboratory Press; (2021).</Citation></Reference><Reference><Citation>Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. . Changes in symptomatology, re-infection and transmissibility associated with SARS-CoV-2 variant B.1.1.7: an ecological study. medRxiv. (2021). 10.1101/2021.01.28.21250680</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.28.21250680</ArticleId><ArticleId IdType="pmc">PMC8041365</ArticleId><ArticleId IdType="pubmed">33857453</ArticleId></ArticleIdList></Reference><Reference><Citation>MHRA. Coronavirus Vaccine - Weekly Summary of Yellow Card Reporting. GOV.UK  (2021). Available online at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting (accessed September 27, 2021).</Citation></Reference><Reference><Citation>Public Health England . COVID-19 Vaccine Surveillance Report - Week 38. London: Public Health England; (2021). p. 33.</Citation></Reference><Reference><Citation>Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK - Office for National Statistics . Available online at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/latest (accessed October 14, 2022).</Citation></Reference><Reference><Citation>Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. . Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. (2021) 27:2127&#x2013;35. 10.1038/s41591-021-01548-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01548-7</ArticleId><ArticleId IdType="pmc">PMC8674129</ArticleId><ArticleId IdType="pubmed">34650248</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England . COVID-19 Vaccine Surveillance Report - Week 33. London: Public Health England; (2021). p. 24.</Citation></Reference><Reference><Citation>ONS . Coronavirus (COVID-19) Latest Insights - Office for National Statistics. Available online at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections#long-covid (accessed October 4, 2022).</Citation></Reference><Reference><Citation>Visual FT, Team DJ. Free to Read: Lockdowns Compared: Tracking Governments' Coronavirus Responses. Available online at: https://ig.ft.com/coronavirus-lockdowns (accessed September 27, 2022).</Citation></Reference><Reference><Citation>UKHSA . Investigation of SARS-CoV-2 Variants: Technical Briefings. GOV.UK. Available online at: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings (accessed September 27, 2022).</Citation></Reference><Reference><Citation>National Audit Office . Test and Trace in England &#x2013; Progress Update. National Audit Office. p. 85.</Citation></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. . Effectiveness of COVID-19 vaccines against the B16172 (Delta) variant. N Engl J Med. (2021) 385:585&#x2013;94. 10.1056/NEJMoa2108891</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>